Michael H Pillinger

Biosketch / Results /

Michael Pillinger

Professor, Department of Medicine;Professor, Department of Biochemistry and Molecular Pharmacology
Medicine

Contact Info

Address
227 East 30th Street
New York, NY 10016

646/501-2722
Michael.Pillinger@nyumc.org

Research Summary

In rheumatoid arthritis (RA) the tissues of the involved joints assume inflammatory, autoimmune and pseudoneoplastic features. The cells contributing to these phenotypes include neutrophils, which accumulate in the RA joint space, and synovial fibroblasts (SFs), which proliferate in great numbers in the RA synovium (pannus) and secrete matrix metalloproteinases (MMPs) that participate in the destruction of cartilage.
The mitogen-activated protein kinases (MAPKs) include the Erks, Jnks and p38. Our laboratory is interested in the role of MAPKs on neutrophils and SF regulation. We are especially interested in the role of Erks. We have observed that, in neutrophils, Erk is rapidly activated in response to chemoattractants and regulates neutrophil adhesion, a critical early step in the acute inflammation. In SFs we have shown that Erk regulates proliferation, but also the release of some (MMP-1,3,9) but not other (MMP-13) metalloproteinases. Interestingly, high-dose salicylates (doses achievable in patients but in excess of those needed to inhibit cyclooxygenase) inhibit Erk in both neutrophils and SFs, and concordantly inhibit neutrophil adhesion and SF MMP release. Non-salicylate nonsteroidals also inhibit cyclooxygenase but do not reproduce these effects. Indeed, COX inhibition actually leads to enhancement of MMP release from synovial fibroblasts.
Our present aims are threefold: 1) to understand the mechanisms through which Erk positively regulates neutrophil adhesion; 2) to understand the cross talk between prostaglandin production and Erk activation in SF responses; 3) to understand the mechanisms through which salicylates inhibit Erk, as a clue into how Erk, and other signaling pathways, may be pharmacologically targeted. A better understanding of these phenomena may lead to new approaches, and new agents, for the treatment of RA.}

Research Interests

Signal transduction and the regulation of cells involved in inflammation and rheumatoid arthritis

Inpatient Gout: A Review
Fisher, Mark C; Pillinger, Michael H; Keenan, Robert T
2014-10-13; 1523-3774,Current rheumatology reports - id: 1300242, year: 2014 JOURNAL ARTICLE

The causes of drug-induced muscle toxicity
Jones, Jonathan D; Kirsch, Hannah L; Wortmann, Robert L; Pillinger, Michael H
2014-09-11; 1040-8711,Current opinion in rheumatology - id: 1181132, year: 2014 JOURNAL ARTICLE

Hyperuricemia, Gout, and Related Comorbidities: Cause and Effect on a Two-Way Street
Karis, Elaine; Crittenden, Daria B; Pillinger, Michael H
2014-06-20; 0038-4348,Southern medical journal - id: 1036702, year: 2014 REVIEW

Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both.
Krasnokutsky, Svetlana; Keenan, Robert T; Schneck, Laura; Tenner, Craig; Strauss, Helene; Crittenden, Daria; Lehmann, Aaron; Pillinger, Michael H
2015-01-29; 2326-5205,Arthritis & rheumatology - id: 1443932, year: 2014

Designing and Implementing INTREPID, an Intensive Program in Translational Research Methodologies for New Investigators
Plottel, Claudia S; Aphinyanaphongs, Yindalon; Shao, Yongzhao; Micoli, Keith J; Fang, Yixin; Goldberg, Judith D; Galeano, Claudia R; Stangel, Jessica H; Chavis-Keeling, Deborah; Hochman, Judith S; Cronstein, Bruce N; Pillinger, Michael H
2014-08-03; 1752-8062,Clinical & translational science - id: 1089772, year: 2014 JOURNAL ARTICLE